Thursday, July 31, 2014 Last update: 4:33 AM
FreshNews.com - All Company Technology News Since 1996

Surveyed U.S. Psychiatrists Would Prescribe Otsuka/Lundbeck's Brexpiprazole to 12 Percent of Their Treatment-Resistant Depression Patients

Companies mentioned in this article: Decision Resources Group

BURLINGTON, Mass., June 23, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (TRD) and would prescribe Otsuka/Lundbeck's emerging atypical antipsychotic brexpiprazole to a mean 12 percent of their drug-treated TRD patients in 2015. This value is slightly lower than the 16 percent patient share surveyed psychiatrists currently estimate for Bristol-Myers Squibb/Otsuka's Abilify. Additionally, nearly one-third of surveyed psychiatrists willing to prescribe brexpiprazole would be most compelled to switch their TRD patients from adjunctive treatment with Abilify if brexpiprazole offered a lower risk of restlessness and/or akathisia (restless movements, inner restlessness and distress) compared to Abilify.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the Physician and Payer Forum report entitled U.S. Prescriber and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression Amid a Crowded and Increasingly Genericized Market include:

    --  Physician approaches to TRD treatment: Surveyed primary care physicians
        (PCPs) and psychiatrists indicate that similar percentages of their
        patients with major depressive disorder (MDD) have TRD (approximately
        one-third), and they take comparable treatment steps to manage their TRD
        patients. Responses from surveyed physicians indicate that increasing
        the therapeutic dose followed by switching among the selective serotonin
        and/or norepinephrine reuptake inhibitors are the most common early-line
        approaches in treatment of TRD patients; antipsychotic drugs are most
        likely to be added as the third line of therapy or later.
    --  Hurdles for recently launched antidepressants: The survey data generally
        finds that physicians encounter minimal reimbursement hurdles when
        prescribing branded antidepressants. However, responses from surveyed
        managed care organization directors suggest that newer-to-market agents
        Forest Laboratories/Pierre Fabre's Fetzima, Takeda/Lundbeck's Brintellix
        and Dainippon Sumitomo/Sunovion's Latuda are in danger of remaining
        excluded from Medicare prescription drug formularies in one year's time,
        likely due to the widespread availability of inexpensive generics and
        greater cost containment pressures on these plans compared with
        commercial plans.

Comments from Decision Resources Group Principal Business Insights Analyst Natalie Taylor, Ph.D.:

    --  "A larger percentage of surveyed PCPs responded they have prescribed
        Brintellix versus the percentage that reported prescribing Fetzima, and
        almost all surveyed PCPs who are familiar with Brintellix but have not
        yet prescribed the drug expect to prescribe it in the next 12 months. We
        note that a high percentage of surveyed PCPs and psychiatrists who have
        prescribed Brintellix perceive it to effectively decrease depressive
        symptoms in TRD patients and find it to have a high response rate."
    --  "Our survey results suggest that outpatient visits and hospitalizations
        contribute substantially to total spending for depression compared with
        drug spend, presumably because most current antidepressant drugs are
        available as inexpensive generics. Because TRD often requires multiple
        outpatient visits and carries a greater risk of hospitalization than
        MDD, payers may offer favorable reimbursement status to effective
        therapies for this patient population to preemptively reduce overall
        spend."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group